DEVOURED
Neuralink's China Rival Targets Obesity With ‘Electronic' GLP-1
Chinese neurotech company BrainCo is developing a brain-stimulating wearable device designed to suppress appetite as an alternative to GLP-1 weight-loss drugs.
What: BrainCo is building a wearable that uses brain-computer interface (BCI) technology to modulate neural signals linked to hunger. The company aims for a market release within two to three years, targeting China first, then potentially the US.
Why it matters: The rise of electronic, non-invasive BCI devices represents a potential non-pharmacological disruption to the booming market currently dominated by GLP-1 injectables.
Decoder
- GLP-1: Glucagon-like peptide-1 receptor agonists, a class of drugs like semaglutide that regulate appetite and blood sugar.
Original article
BrainCo, a Chinese neurotech company, is developing a wearable device that suppresses appetite by stimulating the brain. It aims to bring the device to market within the next two to three years. The device will launch first in China before potentially expanding to the US. BrainCo currently markets brain-computer interface-enabled headsets to address neurological disorders such as autism, ADHD, and insomnia. Its devices can collect, decode, and stimulate neural signals.
Explore all 53 articles in today's digest
Fresh dev news, AI-digested daily. Never miss a trend at devoured.fyi